Eisai
E24939
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
multinational corporation
→
pharmaceutical company → public company → |
| collaboratesWith |
Biogen
→
other global pharmaceutical companies → |
| country |
Japan
→
|
| developed |
Aricept
→
Donepezil → Lecanemab → Leqembi → |
| developedForIndication |
Aricept – Alzheimer’s disease
→
Donepezil – Alzheimer’s disease → Lecanemab – Alzheimer’s disease → Leqembi – Alzheimer’s disease → |
| engagesIn |
clinical trials
→
drug development → drug discovery → |
| focusesOn |
Alzheimer’s disease
→
cancer → neurology → oncology → |
| foundedIn |
Japan
→
|
| hasProduct |
Aricept
→
Donepezil → Lecanemab → Leqembi → |
| hasResearchArea |
immuno-oncology
→
neurodegenerative diseases → oncology therapeutics → |
| hasTherapeuticArea |
central nervous system disorders
→
epilepsy → hematologic malignancies → solid tumors → |
| headquartersLocation |
Japan
→
Tokyo → |
| industry |
biotechnology
→
pharmaceutical industry → |
| knownFor |
Alzheimer’s disease therapies
→
neurology products → oncology products → |
| listedOn |
Tokyo Stock Exchange
→
|
| operatesIn |
Asia
→
Europe → North America → global markets → |
| specializesIn |
prescription drugs
→
research and development → |
| tickerSymbol |
4523
→
|
Referenced by (4)
| Subject (surface form when different) | Predicate |
|---|---|
|
Aduhelm
→
|
coDevelopedBy |
|
Biogen
→
|
collaboratesWith |
|
Leqembi
→
|
developedBy |
|
Leqembi
→
|
hasBrandOwner |